BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 15659130)

  • 1. A prospective 3-yr evaluation of tacrolimus-based immunosuppressive therapy in immunological high risk renal allograft recipients.
    Zaltzman JS; Boucher A; Busque S; Halloran PF; Landsberg DN; McAlister VC; Russell D; Shoker A; Shapiro J; Tchervenkov JI; Ferguson R
    Clin Transplant; 2005 Feb; 19(1):26-32. PubMed ID: 15659130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
    Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
    Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
    Lim WH; Chadban SJ; Campbell S; Dent H; Russ GR; McDonald SP
    Nephrology (Carlton); 2010 Apr; 15(3):368-76. PubMed ID: 20470309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen.
    Irish W; Sherrill B; Brennan DC; Lowell J; Schnitzler M
    Transplantation; 2003 Dec; 76(12):1686-90. PubMed ID: 14688516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
    Cheung CY; Liu YL; Wong KM; Chan HW; Chan YH; Wong HS; Chak WL; Choi KS; Chau KF; Shek CC; Li CS
    Nephrology (Carlton); 2008 Jun; 13(3):251-5. PubMed ID: 18221256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
    Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
    Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative single-bolus high-dose antithymocyte globulin as induction therapy in sensitized renal transplant recipients.
    Wang D; Wu WZ; Yang SL; Chen JH; Tan JM
    Chin Med J (Engl); 2006 Oct; 119(20):1683-8. PubMed ID: 17097014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience.
    Thielke JJ; West-Thielke PM; Herren HL; Bareato U; Ommert T; Vidanovic V; Campbell-Lee SA; Tzvetanov IG; Sankary HN; Kaplan B; Benedetti E; Oberholzer J
    Transplantation; 2009 Jan; 87(2):268-73. PubMed ID: 19155983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of tacrolimus compared with cyclosporin microemulsion in primary SPK transplantation: 3-year results of the Euro-SPK 001 trial.
    Saudek F; Malaise J; Boucek P; Adamec M;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii3-10, ii62. PubMed ID: 15814547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
    Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
    Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steroid avoidance immunosuppression in low-risk kidney transplant recipients.
    Heilman RL; Mazur MJ; Reddy KS; Moss A; Post D; Mulligan D
    Transplant Proc; 2005 May; 37(4):1785-8. PubMed ID: 15919466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two doses of daclizumab with delayed introduction of low-dose tacrolimus in elderly recipients of cadaveric renal transplants from donors >55 years of age.
    Osuna A; Gentil MA; Capdevila L; Cantarell C; Mazuecos A; Pereira P; Rodríguez-Algarra G; González-Molina M;
    Transplant Proc; 2005 Apr; 37(3):1438-40. PubMed ID: 15866630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to reach tacrolimus maximum blood concentration,mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients.
    Kuypers DR; Vanrenterghem Y
    Clin Ther; 2004 Nov; 26(11):1834-44. PubMed ID: 15639695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generic tacrolimus (Pan Graf) in renal transplantation: an experience of 155 recipients in India.
    Guleria S; Kamboj M; Chatterjee A; Sharma M; Awasthy V; Dinda A; Mahajan S; Bhowmik D; Gupta S; Agarwal SK; Tiwari SC
    Transplant Proc; 2008 Sep; 40(7):2237-9. PubMed ID: 18790202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure.
    Waid T;
    Clin Transplant; 2005 Oct; 19(5):573-80. PubMed ID: 16146546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One year results of preoperative single bolus ATG-Fresenius induction therapy in sensitized renal transplant recipients.
    Wang D; Chen JH; Wu WZ; Yang SL; Wu GJ; Wang H; Tan JM
    Transplant Proc; 2007; 39(1):69-72. PubMed ID: 17275476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rejection after simultaneous pancreas-kidney transplantation.
    Arbogast H; Malaise J; Illner WD; Tarabichi A; Dieterle C; Landgraf R; Land W;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii11-7, ii62. PubMed ID: 15814544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs. cyclosporin microemulsion.
    Filler G; Webb NJ; Milford DV; Watson AR; Gellermann J; Tyden G; Grenda R; Vondrak K; Hughes D; Offner G; Griebel M; Brekke IB; McGraw M; Balzar E; Friman S; Trompeter R
    Pediatr Transplant; 2005 Aug; 9(4):498-503. PubMed ID: 16048603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.